Dive Brief:
- The biotech company Advanced Cell Technology (ACT) is focused on R&D of regenerative medicine and cell therapy technology to treat eye-related diseases and disorders.
- The new patent strengthens ACT’s IP position around core cell technology. It covers a novel approach to commercial-scale manufacturing of an allogenic, off-the-shelf immunotherapy platform.
- The company has a rich pipeline that includes therapies in development from the preclinical level to advanced-stage development almost ready for submission for approval.
Dive Insight:
At the moment, ACT’s preclinical program includes various cell therapies being developed to treat not only ocular disorders, but also autoimmune, inflammatory, and wound healing-related disorders.
On the other end of the spectrum, ACT’s most advanced products are in clinical trials for treatment of age-related macular degeneration, Stagardt’s macular degeneration, and myopic macular degeneration. The company is a leader in the regenerative medicine field.